Intelligent pest management company Exosect has announced the completion of its latest round of funding, gathered from its existing investor base, which it says will enable the introduction of the second phase of its commercial strategy based on its patented platform technology, Entostat powder.

Entostat powder is the platform technology for Exosect's entire range of products, derived from a natural food grade wax from palm trees and acting as a delivery system for a wide range of chemistry.

The second phase of its strategy will focus on the co-development of a range of pipeline solutions based on Entostat formulations, together with out-licensing specific product applications and product registrations.

'This investment is a further testament to the potential of our platform technology, Entostat,' said Martin Brown, managing director at Exosect.

'When the company was spun out of Southampton University 10 years ago, we were focused on developing pheromone products in agriculture,' he continued. 'Throughout this period, our research has revealed the wider potential of Entostat powder as a targeted delivery platform for a broad range of active ingredients across numerous sectors. Implementing this strategy will ensure that we can capitalise on these new and exciting opportunities.'

The move follows on from the successful divestment of a bee health product for the control of Varroa mite on honey bees to Bayer CropScience in November last year, along with a number of commercial collaborative projects that are currently in the research and development pipeline.

Topics